EGFR-IN-35

Modify Date: 2024-04-08 05:47:51

EGFR-IN-35 Structure
EGFR-IN-35 structure
Common Name EGFR-IN-35
CAS Number 2711105-57-4 Molecular Weight 489.96
Density N/A Boiling Point N/A
Molecular Formula C25H24ClN7O2 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of EGFR-IN-35


EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11)[1].

 Names

Name EGFR-IN-35

 EGFR-IN-35 Biological Activity

Description EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11)[1].
Related Catalog
References

[1]. Yihan Wang, et al. Substituted acrylamide derivatives and compositions thereof and their uses. Patent WO2021185348A1.

 Chemical & Physical Properties

Molecular Formula C25H24ClN7O2
Molecular Weight 489.96